News | May 14, 2025
Bayer confirms 2025 targets after solid start to the year
EBITDA before special items decreases to €4.08 billion (7.4%)
EBITDA before special items decreases to €4.08 billion (7.4%)
Glatiramer Acetate is the generic version of Copaxone 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care
IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
30th Lab in Thyrocare’s expanding network to bring advanced, affordable diagnostics in Bihar and beyond
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
The Board has also approved plans to invest approximately Rs. 500 crores including cost of land in developing a state-of-the-art, 400-bed super specialty hospital
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Subscribe To Our Newsletter & Stay Updated
